Summary
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 53 molecules. Out of which approximately 53 molecules are developed by companies. The latest report Tyrosine Protein Kinase JAK1 - Drugs In Development, 2022, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body. The molecules developed by companies in Archived (Marketed), Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 7, 10, 10, 17, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.
Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Infectious Disease, Respiratory, Central Nervous System, Cardiovascular, Hematological Disorders, Metabolic Disorders, Genetic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Ulcerative Colitis, Psoriasis, Inflammatory Bowel Disease, Graft Versus Host Disease (GVHD), Systemic Lupus Erythematosus, Vitiligo, Ankylosing Spondylitis (Bekhterev's Disease), Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Inflammation, Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Autoimmune Disorders, Dermatitis (Eczema), Diffuse Large B-Cell Lymphoma, Multiple Sclerosis, Peripheral T-Cell Lymphomas (PTCL), Sicca Syndrome (Sjogren), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Asthma, B-Cell Non-Hodgkin Lymphoma, Bronchiolitis Obliterans, Chronic Lymphocytic Leukemia (CLL), Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome, Cutaneous T-Cell Lymphoma, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hemophagocytic Lymphohistiocytosis, Hidradenitis Suppurativa, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Prurigo, Psoriatic Arthritis, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Triple-Negative Breast Cancer (TNBC), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Aicardi-Goutieres Syndrome (AGS), Allergies, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Arthritis, Auto Inflammatory Disease, Axial Spondyloarthritis, B-Cell Chronic Lymphocytic Leukemia, Breast Hyperplasia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Chronic Kidney Disease (Chronic Renal Failure), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cytokine Release Syndrome (Cytokine Storm), Diabetic Macular Edema, Endometrial Cancer, Eosinophilic Esophagitis, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Focal Segmental Glomerulosclerosis (FSGS), Follicular Lymphoma, Gastric Cancer, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hairy Cell Leukemia, Hand Dermatitis, Hematopoietic Stem Cell Transplantation, Hepatocellular Carcinoma, Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Idiopathic Pulmonary Fibrosis, Juvenile Arthritis, Keratoconjunctivitis Sicca (Dry Eye), Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lipodystrophy (Lipoatrophy), Lupus Erythematosus, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Mild Cognitive Impairment, Myeloproliferative Disorders, Myxoid Liposarcoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Oligoarticular Idiopathic Juvenile Arthritis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Pruritus, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Secondary Myelofibrosis, Sezary Syndrome, Skin Cancer, Solid Tumor, Spondyloarthritis (Spondyloarthropathy), Squamous Cell Carcinoma, Synovial Sarcoma, Systemic Idiopathic Juvenile Arthritis, T-Cell Lymphomas, Takayasu Arteritis, Thrombocythemia Myelofibrosis and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
Aclaris Therapeutics Inc
Alexion Pharmaceuticals Inc
Aqilion AB
Ashvattha Therapeutics LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Celon Pharma SA
Concert Pharmaceuticals Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Eli Lilly and Co
EQRx Inc
Galapagos NV
GlaxoSmithKline Plc
Han Wha Pharma Co Ltd
Hangzhou East China Pharmaceutical Group Co Ltd
HK inno.N Corp
Impetis Biosciences Ltd
Incyte Corp
Japan Tobacco Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Kinaset Therapeutics Inc
Lynk Pharmaceutical Hangzhou Co Ltd
Merck & Co Inc
Nippon Shinyaku Co Ltd
Pfizer Inc
Sareum Holdings Plc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
Sierra Oncology Inc
Simcere Pharmaceutical Group Ltd
The United Laboratories International Holdings Ltd
Theravance Biopharma Inc
TLL Pharmaceutical LLC
Wuxi Fuxin Pharmaceutical Research and Development Co Ltd
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
(elsubrutinib + upadacitinib) - Drug Profile
Product Description
Mechanism Of Action
History of Events
A-223 - Drug Profile
Product Description
Mechanism Of Action
abrocitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
AQ-280 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ARQ-255 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ATI-1777 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ATI-501 - Drug Profile
Product Description
Mechanism Of Action
History of Events
baricitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDD-2603 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
CJ-15314 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CPL-409116 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CS-12192 - Drug Profile
Product Description
Mechanism Of Action
delgocitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
deuruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Inhibit JAK1 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
DZD-4205 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EQ-121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
filgotinib maleate - Drug Profile
Product Description
Mechanism Of Action
History of Events
FZJ-003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GLPG-0555 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GLPG-3121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
INCB-54707 - Drug Profile
Product Description
Mechanism Of Action
History of Events
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
History of Events
ivarmacitinib sulfate - Drug Profile
Product Description
Mechanism Of Action
History of Events
KFPH-018 - Drug Profile
Product Description
Mechanism Of Action
LNK-01001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
NS-229 - Drug Profile
Product Description
Mechanism Of Action
OB-756 - Drug Profile
Product Description
Mechanism Of Action
Opzelura - Drug Profile
Product Description
Mechanism Of Action
History of Events
peficitinib hydrobromide - Drug Profile
Product Description
Mechanism Of Action
History of Events
PNQ-401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PNQ-701 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SDC-1801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SDC-1802 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit JAK1 and JAK3 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Moleucle to Inhibit JAK 1 and JAK 2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
History of Events
TLL-018 - Drug Profile
Product Description
Mechanism Of Action
History of Events
upadacitinib ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
VC-005 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VR-588 - Drug Profile
Product Description
Mechanism Of Action
History of Events
WXFL-10203614 - Drug Profile
Product Description
Mechanism Of Action
WXSH-0150 - Drug Profile
Product Description
Mechanism Of Action
YJC-50018 - Drug Profile
Product Description
Mechanism Of Action
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Mar 07, 2022: Another lifesaving COVID-19 drug identified
Feb 28, 2022: Lynk Pharmaceuticals announces first patient dosed in phase II clinical study of LNK01001in patients with atopic dermatitis
Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn's disease
Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn's disease
Feb 18, 2022: Dizal Pharmaceutical receives U.S. FDA Fast Track Designation for DZD4205 (Golidocitinib) for the treatment of refractory or relapsed peripheral T-cell lymphoma
Feb 17, 2022: WHO recommends Baricitinib for Covid-19
Feb 02, 2022: Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
Jan 28, 2022: Updates on OLUMIANT (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Jan 25, 2022: Sierra Oncology provides financial update to support the future commercialization of momelotinib
Jan 25, 2022: Sierra Oncology announces momelotinib achieved statistically significant benefit on symptoms, anemia and splenic size in the pivotal MOMENTUM study for myelofibrosis
Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial
Jan 19, 2022: Momelotinib review article published in Journal of Hematology & Oncology highlights importance of anemia benefit for Myelofibrosis Patients
Jan 18, 2022: Sierra Oncology updates topline data timing for pivotal phase 3 trial of momelotinib in myelofibrosis
Jan 18, 2022: Jyseleca (filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain
Jan 17, 2022: MSF responds to latest WHO recommendation for COVID-19 medicine baricitinib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Indications, 2022 (Contd..4)
Number of Products under Development by Indications, 2022 (Contd..5)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Products under Development by Companies, 2022 (Contd..10)
Products under Development by Companies, 2022 (Contd..11)
Products under Development by Companies, 2022 (Contd..12)
Products under Development by Companies, 2022 (Contd..13)
Products under Development by Companies, 2022 (Contd..14)
Products under Development by Companies, 2022 (Contd..15)
Products under Development by Companies, 2022 (Contd..16)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by Aclaris Therapeutics Inc, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Aqilion AB, 2022
Pipeline by Ashvattha Therapeutics LLC, 2022
Pipeline by Astellas Pharma Inc, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Celon Pharma SA, 2022
Pipeline by Concert Pharmaceuticals Inc, 2022
Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by EQRx Inc, 2022
Pipeline by Galapagos NV, 2022
Pipeline by GlaxoSmithKline Plc, 2022
Pipeline by Han Wha Pharma Co Ltd, 2022
Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022
Pipeline by HK inno.N Corp, 2022
Pipeline by Impetis Biosciences Ltd, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Pipeline by Jiangsu Vcare PharmaTech Co Ltd, 2022
Pipeline by Kinaset Therapeutics Inc, 2022
Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Nippon Shinyaku Co Ltd, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Sareum Holdings Plc, 2022
Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Pipeline by Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd, 2022
Pipeline by Sierra Oncology Inc, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by The United Laboratories International Holdings Ltd, 2022
Pipeline by Theravance Biopharma Inc, 2022
Pipeline by TLL Pharmaceutical LLC, 2022
Pipeline by Wuxi Fuxin Pharmaceutical Research and Development Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Dormant Products, 2022 (Contd..4)
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)
Discontinued Products, 2022 (Contd..2)
List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Type, 2022
